NasdaqCM - Nasdaq Real Time Price USD

KORU Medical Systems, Inc. (KRMD)

Compare
2.6950 -0.0050 (-0.19%)
As of 1:12 PM EDT. Market Open.
Loading Chart for KRMD
DELL
  • Previous Close 2.7000
  • Open 2.7500
  • Bid 1.9500 x 200
  • Ask 3.4600 x 200
  • Day's Range 2.6800 - 2.7500
  • 52 Week Range 1.9780 - 3.0900
  • Volume 3,523
  • Avg. Volume 133,644
  • Market Cap (intraday) 123.58M
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2500
  • Earnings Date Aug 7, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.60

KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.

www.korumedical.com

82

Full Time Employees

December 31

Fiscal Year Ends

Recent News: KRMD

View More

Performance Overview: KRMD

Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

KRMD
9.78%
S&P 500
20.12%

1-Year Return

KRMD
3.41%
S&P 500
32.10%

3-Year Return

KRMD
11.64%
S&P 500
28.60%

5-Year Return

KRMD
28.70%
S&P 500
91.96%

Compare To: KRMD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: KRMD

View More

Valuation Measures

Annual
As of 9/25/2024
  • Market Cap

    123.81M

  • Enterprise Value

    117.32M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.00

  • Price/Book (mrq)

    6.62

  • Enterprise Value/Revenue

    3.81

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -38.16%

  • Return on Assets (ttm)

    -14.10%

  • Return on Equity (ttm)

    -50.25%

  • Revenue (ttm)

    30.82M

  • Net Income Avi to Common (ttm)

    -11.76M

  • Diluted EPS (ttm)

    -0.2500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.46M

  • Total Debt/Equity (mrq)

    21.21%

  • Levered Free Cash Flow (ttm)

    1.05M

Research Analysis: KRMD

View More

Company Insights: KRMD

Research Reports: KRMD

View More

People Also Watch